skip to main content
DOE PAGES title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase

Abstract

Glucokinase and hexokinase from pathogenic protozoa Trypanosoma cruzi are potential drug targets for antiparasitic chemotherapy of Chagas’ disease. These glucose kinases phosphorylate d-glucose with co-substrate ATP and yield glucose 6-phosphate and are involved in essential metabolic pathways, such as glycolysis and the pentose phosphate pathway. An inhibitor class was conceived that is selective for T. cruzi glucokinase (TcGlcK) using structure-based drug design involving glucosamine having a linker from the C2 amino that terminates with a hydrophobic group either being phenyl, p-hydroxyphenyl, or dioxobenzo[b]thiophenyl groups. The synthesis and characterization for two of the four compounds are presented while the other two compounds were commercially available. Four high-resolution X-ray crystal structures of TcGlcK inhibitor complexes are reported along with enzyme inhibition constants (Ki) for TcGlcK and Homo sapiens hexokinase IV (HsHxKIV). These glucosamine analogue inhibitors include three strongly selective TcGlcK inhibitors and a fourth inhibitor, benzoyl glucosamine (BENZ-GlcN), which is a similar variant exhibiting a shorter linker. Carboxybenzyl glucosamine (CBZ-GlcN) was found to be the strongest glucokinase inhibitor known to date, having a Ki of 0.71 ± 0.05 μM. Also reported are two biologically active inhibitors against in vitro T. cruzi culture that were BENZ-GlcN and CBZ-GlcN, with intracellular amastigote growth inhibitionmore » IC50 values of 16.08 ± 0.16 μM and 48.73 ± 0.69 μM, respectively. Furthermore, these compounds revealed little to no toxicity against mammalian NIH-3T3 fibroblasts and provide a key starting point for further drug development with this class of compound.« less

Authors:
 [1];  [1];  [1];  [1];  [2]; ORCiD logo [3];  [1];  [4];  [2];  [1]
  1. Univ. of South Carolina Beaufort, Bluffton, SC (United States)
  2. New York Univ. School of Medicine, NY (United States)
  3. Argonne National Lab. (ANL), Argonne, IL (United States)
  4. North Carolina State Univ., Raleigh, NC (United States)
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States)
Sponsoring Org.:
USDOE Office of Science (SC), Basic Energy Sciences (BES). Scientific User Facilities Division; US National Institutes of Health; NIH-ORIP HEI
OSTI Identifier:
1251207
Alternate Identifier(s):
OSTI ID: 1422460
Grant/Contract Number:  
AC02-06CH11357; GM103499; P41 GM103403; S10 RR029205
Resource Type:
Accepted Manuscript
Journal Name:
Molecular and Biochemical Parasitology
Additional Journal Information:
Journal Volume: 204; Journal Issue: 2; Journal ID: ISSN 0166-6851
Publisher:
Elsevier
Country of Publication:
United States
Language:
ENGLISH
Subject:
59 BASIC BIOLOGICAL SCIENCES; Chagas’ disease; Trypanosoma cruzi; Glucokinase; Hexokinase; Structure-based drug design

Citation Formats

D’Antonio, Edward L., Deinema, Mason S., Kearns, Sean P., Frey, Tyler A., Tanghe, Scott, Perry, Kay, Roy, Timothy A., Gracz, Hanna S., Rodriguez, Ana, and D’Antonio, Jennifer. Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase. United States: N. p., 2016. Web. https://doi.org/10.1016/j.molbiopara.2015.12.004.
D’Antonio, Edward L., Deinema, Mason S., Kearns, Sean P., Frey, Tyler A., Tanghe, Scott, Perry, Kay, Roy, Timothy A., Gracz, Hanna S., Rodriguez, Ana, & D’Antonio, Jennifer. Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase. United States. https://doi.org/10.1016/j.molbiopara.2015.12.004
D’Antonio, Edward L., Deinema, Mason S., Kearns, Sean P., Frey, Tyler A., Tanghe, Scott, Perry, Kay, Roy, Timothy A., Gracz, Hanna S., Rodriguez, Ana, and D’Antonio, Jennifer. Thu . "Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase". United States. https://doi.org/10.1016/j.molbiopara.2015.12.004. https://www.osti.gov/servlets/purl/1251207.
@article{osti_1251207,
title = {Structure-based approach to the identification of a novel group of selective glucosamine analogue inhibitors of Trypanosoma cruzi glucokinase},
author = {D’Antonio, Edward L. and Deinema, Mason S. and Kearns, Sean P. and Frey, Tyler A. and Tanghe, Scott and Perry, Kay and Roy, Timothy A. and Gracz, Hanna S. and Rodriguez, Ana and D’Antonio, Jennifer},
abstractNote = {Glucokinase and hexokinase from pathogenic protozoa Trypanosoma cruzi are potential drug targets for antiparasitic chemotherapy of Chagas’ disease. These glucose kinases phosphorylate d-glucose with co-substrate ATP and yield glucose 6-phosphate and are involved in essential metabolic pathways, such as glycolysis and the pentose phosphate pathway. An inhibitor class was conceived that is selective for T. cruzi glucokinase (TcGlcK) using structure-based drug design involving glucosamine having a linker from the C2 amino that terminates with a hydrophobic group either being phenyl, p-hydroxyphenyl, or dioxobenzo[b]thiophenyl groups. The synthesis and characterization for two of the four compounds are presented while the other two compounds were commercially available. Four high-resolution X-ray crystal structures of TcGlcK inhibitor complexes are reported along with enzyme inhibition constants (Ki) for TcGlcK and Homo sapiens hexokinase IV (HsHxKIV). These glucosamine analogue inhibitors include three strongly selective TcGlcK inhibitors and a fourth inhibitor, benzoyl glucosamine (BENZ-GlcN), which is a similar variant exhibiting a shorter linker. Carboxybenzyl glucosamine (CBZ-GlcN) was found to be the strongest glucokinase inhibitor known to date, having a Ki of 0.71 ± 0.05 μM. Also reported are two biologically active inhibitors against in vitro T. cruzi culture that were BENZ-GlcN and CBZ-GlcN, with intracellular amastigote growth inhibition IC50 values of 16.08 ± 0.16 μM and 48.73 ± 0.69 μM, respectively. Furthermore, these compounds revealed little to no toxicity against mammalian NIH-3T3 fibroblasts and provide a key starting point for further drug development with this class of compound.},
doi = {10.1016/j.molbiopara.2015.12.004},
journal = {Molecular and Biochemical Parasitology},
number = 2,
volume = 204,
place = {United States},
year = {2016},
month = {1}
}

Journal Article:

Citation Metrics:
Cited by: 6 works
Citation information provided by
Web of Science

Save / Share:

Works referenced in this record:

The trypanosomiases
journal, November 2003


The Challenges of Chagas Disease— Grim Outlook or Glimmer of Hope?
journal, December 2007


Chagas disease in Spain, the United States and other non-endemic countries
journal, July 2010


Trypanosoma cruzi and Chagas' Disease in the United States
journal, October 2011

  • Bern, C.; Kjos, S.; Yabsley, M. J.
  • Clinical Microbiology Reviews, Vol. 24, Issue 4
  • DOI: 10.1128/CMR.00005-11

Chemotherapy of trypanosomiases and leishmaniasis
journal, November 2005


Long term evaluation of etiological treatment of Chagas disease with benznidazole
journal, February 2002


Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas' disease
journal, December 2008


Specific chemotherapy of Chagas disease: controversies and advances
journal, November 2003


Glycolysis as a target for the design of new anti-trypanosome drugs
journal, February 2001

  • Verlinde, Christophe L. M. J.; Hannaert, Véronique; Blonski, Casimir
  • Drug Resistance Updates, Vol. 4, Issue 1
  • DOI: 10.1054/drup.2000.0177

Glycolysis in the African Trypanosome: Targeting Enzymes and Their Subcellular Compartments for Therapeutic Development
journal, April 2011

  • Coley, April F.; Dodson, Heidi C.; Morris, Meredith T.
  • Molecular Biology International, Vol. 2011
  • DOI: 10.4061/2011/123702

Molecular and biochemical characterization of hexokinase from Trypanosoma cruzi
journal, February 2003

  • Cáceres, Ana Judith; Portillo, Ramon; Acosta, Hector
  • Molecular and Biochemical Parasitology, Vol. 126, Issue 2
  • DOI: 10.1016/S0166-6851(02)00294-3

Inhibition of Trypanosoma c ruzi Hexokinase by Bisphosphonates
journal, January 2006

  • Hudock, Michael P.; Sanz-Rodríguez, C. E.; Song, Yongcheng
  • Journal of Medicinal Chemistry, Vol. 49, Issue 1
  • DOI: 10.1021/jm0582625

Bisphosphonates as Inhibitors of Trypanosoma cruzi Hexokinase
journal, April 2007

  • Sanz-Rodríguez, Carlos E.; Concepción, Juan L.; Pekerar, Sara
  • Journal of Biological Chemistry, Vol. 282, Issue 17
  • DOI: 10.1074/jbc.M607286200

The anti-trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1
journal, April 2008


Quercetin, a fluorescent bioflavanoid, inhibits Trypanosoma brucei hexokinase 1
journal, February 2011


A Target-Based High Throughput Screen Yields Trypanosoma brucei Hexokinase Small Molecule Inhibitors with Antiparasitic Activity
journal, April 2010

  • Sharlow, Elizabeth R.; Lyda, Todd A.; Dodson, Heidi C.
  • PLoS Neglected Tropical Diseases, Vol. 4, Issue 4
  • DOI: 10.1371/journal.pntd.0000659

Sequencing, Modeling, and Selective Inhibition of Trypanosoma brucei Hexokinase
journal, July 2002


Energy metabolism of trypanosomatids: Adaptation to available carbon sources
journal, September 2006


Experimental and in Silico Analyses of Glycolytic Flux Control in Bloodstream Form Trypanosoma brucei
journal, August 2005

  • Albert, Marie-Astrid; Haanstra, Jurgen R.; Hannaert, Véronique
  • Journal of Biological Chemistry, Vol. 280, Issue 31
  • DOI: 10.1074/jbc.M502403200

Aerobic fermentation of glucose by trypanosomatids
journal, October 1992


Aerobic glucose fermentation by Trypanosoma cruzi axenic culture amastigote-like forms during growth and differentiation to epimastigotes
journal, November 1987

  • Engel, Juan Carlos; Franke de Cazzulo, Berta M.; Stoppani, Andres O. M.
  • Molecular and Biochemical Parasitology, Vol. 26, Issue 1-2
  • DOI: 10.1016/0166-6851(87)90123-X

Differences in Energy Metabolism Between Trypanosomatidae
journal, July 1998


Molecular and biochemical characterization of novel glucokinases from Trypanosoma cruzi and Leishmania spp.
journal, December 2007


Comparative Genomics Reveals Two Novel RNAi Factors in Trypanosoma brucei and Provides Insight into the Core Machinery
journal, May 2012


Tests of cytoplasmic RNA interference (RNAi) and construction of a tetracycline-inducible T7 promoter system in Trypanosoma cruzi
journal, February 2004


The Crystal Structure of Trypanosoma cruzi Glucokinase Reveals Features Determining Oligomerization and Anomer Specificity of Hexose-phosphorylating Enzymes
journal, October 2007

  • Cordeiro, Artur T.; Cáceres, Ana J.; Vertommen, Didier
  • Journal of Molecular Biology, Vol. 372, Issue 5
  • DOI: 10.1016/j.jmb.2007.07.021

Hypothesis: Structures, evolution, and ancestor of glucose kinases in the hexokinase family
journal, April 2005

  • Kawai, Shigeyuki; Mukai, Takako; Mori, Shigetarou
  • Journal of Bioscience and Bioengineering, Vol. 99, Issue 4
  • DOI: 10.1263/jbb.99.320

Crystal Structures of Escherichia coli ATP-Dependent Glucokinase and Its Complex with Glucose
journal, October 2004


Knowledge-based protein secondary structure assignment
journal, December 1995

  • Frishman, Dmitrij; Argos, Patrick
  • Proteins: Structure, Function, and Genetics, Vol. 23, Issue 4
  • DOI: 10.1002/prot.340230412

STRIDE: a web server for secondary structure assignment from known atomic coordinates of proteins
journal, July 2004

  • Heinig, M.; Frishman, D.
  • Nucleic Acids Research, Vol. 32, Issue Web Server
  • DOI: 10.1093/nar/gkh429

Deciphering key features in protein structures with the new ENDscript server
journal, April 2014

  • Robert, Xavier; Gouet, Patrice
  • Nucleic Acids Research, Vol. 42, Issue W1
  • DOI: 10.1093/nar/gku316

Sequencing a protein by X-ray crystallography
journal, July 1978

  • Anderson, Chaeles M.; Stenkamp, Ronald E.; Steitz, Thomas A.
  • Journal of Molecular Biology, Vol. 123, Issue 1
  • DOI: 10.1016/0022-2836(78)90374-1

High resolution crystal structures of yeast hexokinase complexes with substrates, activators, and inhibitors. Evidence for an allosteric control site.
journal, July 1977


Yeast Hexokinase Inhibitors Designed from the 3-D Enzyme Structure Rebuilding
journal, January 1997

  • Willson, Michele; Alric, Isabelle; Perie, Jacques
  • Journal of Enzyme Inhibition, Vol. 12, Issue 2
  • DOI: 10.3109/14756369709035812

Inference of Macromolecular Assemblies from Crystalline State
journal, September 2007


Systematic analysis of domain motions in proteins from conformational change: New results on citrate synthase and T4 lysozyme
journal, February 1998


Structural and functional implications of the hexokinase–nickel interaction
journal, December 2005


Site-directed mutagenesis studies on the determinants of sugar specificity and cooperative behavior of human beta-cell glucokinase.
journal, November 1994


Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
journal, January 1997

  • Lipinski, Christopher A.; Lombardo, Franco; Dominy, Beryl W.
  • Advanced Drug Delivery Reviews, Vol. 23, Issue 1-3
  • DOI: 10.1016/S0169-409X(96)00423-1

Efficient technique for screening drugs for activity against Trypanosoma cruzi using parasites expressing beta-galactosidase.
journal, November 1996

  • Buckner, F. S.; Verlinde, C. L.; La Flamme, A. C.
  • Antimicrobial Agents and Chemotherapy, Vol. 40, Issue 11
  • DOI: 10.1128/AAC.40.11.2592

Activity In Vivo of Anti-Trypanosoma cruzi Compounds Selected from a High Throughput Screening
journal, August 2011

  • Andriani, Grasiella; Chessler, Anne-Danielle C.; Courtemanche, Gilles
  • PLoS Neglected Tropical Diseases, Vol. 5, Issue 8
  • DOI: 10.1371/journal.pntd.0001298

Hexose uptake in Trypanosoma cruzi: structure-activity relationship between substrate and transporter
journal, July 1996

  • Tetaud, Emmanuel; Chabas, Sandrine; Giroud, Christiane
  • Biochemical Journal, Vol. 317, Issue 2
  • DOI: 10.1042/bj3170353

Identification of a New Class of Glucokinase Activators through Structure-Based Design
journal, September 2013

  • Hinklin, Ronald J.; Boyd, Steven A.; Chicarelli, Mark J.
  • Journal of Medicinal Chemistry, Vol. 56, Issue 19
  • DOI: 10.1021/jm401116k

Fast, scalable generation of high‐quality protein multiple sequence alignments using Clustal Omega
journal, January 2011

  • Sievers, Fabian; Wilm, Andreas; Dineen, David
  • Molecular Systems Biology, Vol. 7, Issue 1
  • DOI: 10.1038/msb.2011.75

Protein secondary structure prediction based on position-specific scoring matrices 1 1Edited by G. Von Heijne
journal, September 1999


In Vitro-Reduced Susceptibility to Artemether in P. falciparum and Its Association With Polymorphisms on Transporter Genes
journal, May 2012

  • Bustamante, C.; Folarin, O. A.; Gbotosho, G. O.
  • Journal of Infectious Diseases, Vol. 206, Issue 3
  • DOI: 10.1093/infdis/jis359

PROCHECK: a program to check the stereochemical quality of protein structures
journal, April 1993

  • Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.
  • Journal of Applied Crystallography, Vol. 26, Issue 2
  • DOI: 10.1107/S0021889892009944

The CCP4 suite programs for protein crystallography
journal, September 1994


Ligand efficiency indices for effective drug discovery
journal, April 2007


    Works referencing / citing this record:

    Enzymatic and Structural Characterization of the Naegleria fowleri Glucokinase
    journal, February 2019

    • Milanes, Jillian E.; Suryadi, Jimmy; Abendroth, Jan
    • Antimicrobial Agents and Chemotherapy, Vol. 63, Issue 5
    • DOI: 10.1128/aac.02410-18